[CAS NO. 160800-57-7] AuristatinE
PRODUCTS SPECIFICATIONS [160800-57-7]
DESCRIPTION [160800-57-7]
Overview
| MDL | MFCD25976744 |
|---|---|
| Molecular Weight | 732.01 |
| Molecular Formula | C40H69N5O7 |
| SMILES | CC(C)[C@H](N(C)C)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@@H](CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)=O)OC)C)=O)C(C)C)=O |
Summary
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates . Auristatin E inhibits cell division by blocking the polymerisation of tubulin.
IC50 & Target
|
Auristatin |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years |
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : 100 mg/mL ( 136.61 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.3661 mL | 6.8305 mL | 13.6610 mL |
| 5 mM | 0.2732 mL | 1.3661 mL | 2.7322 mL |
| 10 mM | 0.1366 mL | 0.6831 mL | 1.3661 mL |
References
- [1] Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.
- [2] Li D, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013 Jul;12(7):1255-65.
